HTGC vs. IBB, DNP, ADX, PTY, USA, NUV, GSBD, TY, GAB, and RVT
Should you be buying Hercules Capital stock or one of its competitors? The main competitors of Hercules Capital include iShares Biotechnology ETF (IBB), DNP Select Income Fund (DNP), Adams Diversified Equity Fund (ADX), PIMCO Corporate & Income Opportunity Fund (PTY), Liberty All-Star Equity Fund (USA), Nuveen Municipal Value Fund (NUV), Goldman Sachs BDC (GSBD), Tri-Continental (TY), The Gabelli Equity Trust (GAB), and Royce Value Trust (RVT). These companies are all part of the "investment offices, not elsewhere classified" industry.
Hercules Capital (NYSE:HTGC) and iShares Biotechnology ETF (NASDAQ:IBB) are both mid-cap finance companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings, risk and community ranking.
Hercules Capital has higher revenue and earnings than iShares Biotechnology ETF.
Hercules Capital has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, iShares Biotechnology ETF has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
Hercules Capital pays an annual dividend of $1.60 per share and has a dividend yield of 8.1%. iShares Biotechnology ETF pays an annual dividend of $0.41 per share and has a dividend yield of 0.3%. Hercules Capital pays out 72.7% of its earnings in the form of a dividend.
In the previous week, Hercules Capital had 6 more articles in the media than iShares Biotechnology ETF. MarketBeat recorded 9 mentions for Hercules Capital and 3 mentions for iShares Biotechnology ETF. Hercules Capital's average media sentiment score of 1.04 beat iShares Biotechnology ETF's score of 0.47 indicating that Hercules Capital is being referred to more favorably in the media.
Hercules Capital has a net margin of 69.98% compared to iShares Biotechnology ETF's net margin of 0.00%. Hercules Capital's return on equity of 18.35% beat iShares Biotechnology ETF's return on equity.
Hercules Capital received 304 more outperform votes than iShares Biotechnology ETF when rated by MarketBeat users. However, 67.09% of users gave iShares Biotechnology ETF an outperform vote while only 64.22% of users gave Hercules Capital an outperform vote.
Hercules Capital currently has a consensus price target of $18.56, indicating a potential downside of 5.97%. Given iShares Biotechnology ETF's stronger consensus rating and higher possible upside, analysts clearly believe iShares Biotechnology ETF is more favorable than Hercules Capital.
19.7% of Hercules Capital shares are owned by institutional investors. Comparatively, 62.5% of iShares Biotechnology ETF shares are owned by institutional investors. 1.9% of Hercules Capital shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Hercules Capital beats iShares Biotechnology ETF on 10 of the 16 factors compared between the two stocks.
Get Hercules Capital News Delivered to You Automatically
Sign up to receive the latest news and ratings for HTGC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HTGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hercules Capital Competitors List
Related Companies and Tools
